George Millen: Unscripted

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?

The junior explorer is expanding its footprint in a hot gold district. We analyze the financial mechanics, shareholder impact, and leadership incentives.

Greenway Technologies is leaving the lab. A new deal with a Native-owned firm aims to turn stranded gas into gold, but can the micro-plant economics work?

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

SEALSQ appoints public-private partnership veteran Rolf Gobet to lead its new Geneva Quantum Center, a key move in a well-funded race against quantum threats.

Datavault AI is issuing a 'meme coin' to shareholders. Is this the future of corporate rewards or a regulatory tightrope walk with a speculative asset?

Zoetis boosts its dividend by 6%, but what does this move signal about the company's financial health and the booming global animal care market?

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

How TerraVest's aggressive acquisition spree is reshaping industrial markets and delivering substantial returns to shareholders. Dive into the strategy.

Nasdaq-listed Caliber moves beyond passive holding, staking 75,000 LINK to actively generate yield. A look at the high-stakes strategy bridging Wall Street and Web3.

SSC's 37th dividend payment signals stability, but high payout ratios raise questions. Is management's growth-and-buyback strategy the right bet?

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Copper Quest diversifies from copper, acquiring a high-grade gold mine and adding 150+ years of mining expertise to its board and advisory team.

Impressive new trial data for MDNA11 could disrupt the multi-billion dollar immunotherapy market, offering real hope where standard treatments now fail.

Exodus is using its Bitcoin treasury to buy a payments firm, but declining user metrics and a change in disclosure raise questions about this bold strategy.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.